Breaking News Instant updates and real-time market news.

JNJ

Johnson & Johnson

$129.80

0.89 (0.69%)

07:02
01/11/19
01/11
07:02
01/11/19
07:02

Johnson & Johnson announces completion of offer for Ci:z Holdings

Johnson & Johnson announced that the conditions to its public tender offer for all of the outstanding shares of Ci:z Holdings not already held by Johnson & Johnson or its affiliates that was previously announced on October 23, 2018, have been satisfied and the offering period for the tender offer has expired. There were 20,004,934 shares of the company tendered in the tender offer, representing 41% of the outstanding shares of the company. Johnson & Johnson will acquire all tendered shares for 5,900 per share and will purchase additional shares of the company through the acquisition of CIC Corporation, the ownership vehicle of the company's founder, Dr. Yoshinori Shirono. As of the expiration of the offering period, the shares tendered in the tender offer, together with shares already held by Johnson & Johnson or its affiliates and the shares to be acquired through the acquisition of CIC, will give Johnson & Johnson an aggregate ownership interest in the company of 89%. The settlement of the tender offer and the acquisition of CIC will be completed by January 17, 2019. Following settlement of the tender offer and the acquisition of CIC, Johnson & Johnson plans to acquire the remaining shares of the company that were not tendered in the tender offer through a share consolidation under Japanese law during the first half of 2019 and take appropriate actions to delist the company from the Tokyo Stock Exchange.

  • 22

    Jan

  • 27

    Jan

  • 18

    Feb

JNJ Johnson & Johnson
$129.80

0.89 (0.69%)

12/20/18
WELS
12/20/18
NO CHANGE
WELS
Outperform
No change in talc litigation risk for Johnson & Johnson, says Wells Fargo
Wells Fargo analyst Larry Biegelsen notes that the NY Times reported that Johnson & Johnson has lost its bid to overturn the $4.7B in a talc trial in St. Louis in July 2018. After checking with the company, the analyst is "able to confirm" that the decision relates to the trial judge denying Johnson & Johnson's post trial motion to set aside the $4.7B verdict. Biegelsen understands that the company had to file this motion in order to file its actual appeal of the decision with the appellate court. As such, he believes the judge's decision should not materially affect the overall talc situation for Johnson & Johnson. Wells Fargo has an Outperform rating on the shares.
01/02/19
SBSH
01/02/19
NO CHANGE
SBSH
Citi makes four rating changes in Medical Devices, 'warning up' to J&J
Citi analyst Amit Hazan issued his 2019 preview for Medical Devices, which included four rating changes. The analyst upgraded both Zimmer Biomet (ZBH) and Baxter International (BAX) to Buy from Neutral, downgraded Medtronic (MDT) to Neutral from Buy and downgraded Abbott Laboratories (ABT) to Sell from Neutral. He also kept Buy ratings on Intuitive Surgical (ISRG) and Boston Scientific (BSX), but adds he's "relatively more cautious." Further, Hazan kept a Sell rating on Edwards Lifesciences (EW) and says he's "warming up" to Neutral-rated Johnson & Johnson (JNJ). The analyst expects "fairly stable" fundamentals for the group in 2019, with "modest slowdowns" in organic sales and earnings growth.
01/04/19
CANT
01/04/19
NO CHANGE
Target $100
CANT
Overweight
Cantor Fitzgerald analysis suggests others could bid for Celgene
Cantor Fitzgerald analyst Alethia Young reiterates an Overweight rating on Celgene (CELG) with a $100 price target after the company reached an agreement to be acquired by Bristol-Myers Squibb (BMY). Bristol "likely got a good deal, although Celgene has intellectual property and pipeline uncertainties that are key moving pieces," Young tells investors in a research note. Her estimated net present value for Celgene is $80B, assuming some cost synergies, versus the $74B equity valuation in the Bristol deal, excluding the contingent value rights. Young's analysis indicates that companies like Amgen (AMGN) and Johnson & Johnson (JNJ) "could potentially achieve greater commercial synergies." However, the analyst thinks Celgene shareholders "may be satisfied with the current deal after quite a roller-coaster over the past 18 months."
01/04/19
BTIG
01/04/19
NO CHANGE
Target $17
BTIG
Buy
Veracyte price target raised to $17 from $15 at BTIG
BTIG analyst Sung Ji Nam raised his price target on Veracyte (VCYT) to $17 and kept the Buy rating on the shares after its announced long term partnership with Johnson & Johnson (JNJ) yesterday. The analyst says the collaboration aims to accelerate the development of the first nasal swab test for early lung cancer detection and involve the two companies sharing existing data and samples from clinical studies. Sung Ji Nam states that the deal should lead to acceleration of next -gen Percepta launch, adding that the nasal swab test development could quadruple the company's total addressable market value in the U.S. alone.

TODAY'S FREE FLY STORIES

FCSC

Fibrocell Science

$2.03

0.03 (1.50%)

16:55
01/18/19
01/18
16:55
01/18/19
16:55
Syndicate
Breaking Syndicate news story on Fibrocell Science »

Fibrocell Science files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENLC

EnLink Midstream

$11.75

0.4 (3.52%)

, ENLK

EnLink Midstream Partners

$13.58

0.51 (3.90%)

16:49
01/18/19
01/18
16:49
01/18/19
16:49
Conference/Events
EnLink Midstream Partners to hold a special shareholder meeting »

Special Shareholder…

ENLC

EnLink Midstream

$11.75

0.4 (3.52%)

ENLK

EnLink Midstream Partners

$13.58

0.51 (3.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

FDX

FedEx

$176.97

3.72 (2.15%)

16:49
01/18/19
01/18
16:49
01/18/19
16:49
Hot Stocks
FedEx establishes voluntary buyout program for U.S. workers »

FedEx said in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

  • 31

    Jan

  • 03

    Mar

  • 19

    Mar

  • 01

    Apr

  • 02

    Apr

ENLK

EnLink Midstream Partners

$13.58

0.51 (3.90%)

, ENLC

EnLink Midstream

$11.75

0.4 (3.52%)

16:48
01/18/19
01/18
16:48
01/18/19
16:48
Conference/Events
EnLink Midstream Companies to hold a special shareholder meeting »

Special Shareholder…

ENLK

EnLink Midstream Partners

$13.58

0.51 (3.90%)

ENLC

EnLink Midstream

$11.75

0.4 (3.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

MKL

Markel

$1,067.03

13.52 (1.28%)

16:36
01/18/19
01/18
16:36
01/18/19
16:36
Hot Stocks
Markel says Anthony Belisle, Alissa Fredricks no longer with company »

Markel Corporation said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NILSY

Norilsk Nickel

$0.00

(0.00%)

16:35
01/18/19
01/18
16:35
01/18/19
16:35
Downgrade
Norilsk Nickel rating change  »

Norilsk Nickel downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$130.65

1.54 (1.19%)

, ABBV

AbbVie

$89.51

2.28 (2.61%)

16:33
01/18/19
01/18
16:33
01/18/19
16:33
Hot Stocks
AbbVie: Phase 3 study of ibrutinib did not meet primary endpoint »

AbbVie (ABBV) announced…

JNJ

Johnson & Johnson

$130.65

1.54 (1.19%)

ABBV

AbbVie

$89.51

2.28 (2.61%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 25

    Jan

  • 27

    Jan

  • 28

    Jan

  • 18

    Feb

  • 18

    May

FOMX

Foamix

$3.70

-0.14 (-3.65%)

16:32
01/18/19
01/18
16:32
01/18/19
16:32
Conference/Events
Foamix to host research and development day »

Research and Development…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

16:30
01/18/19
01/18
16:30
01/18/19
16:30
Options
Preliminary option volume of 26.9M today »

Preliminary option volume…

NBRV

Nabriva Therapeutics

$1.97

-0.01 (-0.51%)

16:27
01/18/19
01/18
16:27
01/18/19
16:27
Conference/Events
Nabriva Therapeutics to host analyst and investor meeting »

Analyst and Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 30

    Apr

VLRS

Volaris

$7.50

0.04 (0.54%)

16:21
01/18/19
01/18
16:21
01/18/19
16:21
Conference/Events
International Aviation Club to host monthly luncheon meeting »

Enrique Beltranena, CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
01/18/19
01/18
16:20
01/18/19
16:20
Options
Closing CBOE SPX and VIX Index summary for January 18th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
01/18/19
01/18
16:17
01/18/19
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
01/18/19
01/18
16:16
01/18/19
16:16
Technical Analysis
NYSE market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTSV

Forty Seven

$14.48

-0.57 (-3.79%)

16:14
01/18/19
01/18
16:14
01/18/19
16:14
Conference/Events
Forty Seven to hold KOL breakfast symposium »

Key Opinion Leader…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$302.26

-45.18 (-13.00%)

, WMT

Walmart

$97.75

1.01 (1.04%)

16:14
01/18/19
01/18
16:14
01/18/19
16:14
On The Fly
Fly Intel: Wall Street's top stories for Friday »

Stocks opened higher and…

TSLA

Tesla

$302.26

-45.18 (-13.00%)

WMT

Walmart

$97.75

1.01 (1.04%)

CVS

CVS Health

$65.49

2.13 (3.36%)

NFLX

Netflix

$339.20

-14.02 (-3.97%)

FB

Facebook

$150.01

1.77 (1.19%)

AAPL

Apple

$156.85

0.99 (0.64%)

QCOM

Qualcomm

$55.26

0.44 (0.80%)

FND

Floor & Decor

$31.99

2.34 (7.89%)

OZK

Bank OZK

$32.07

4.47 (16.20%)

VFC

VF Corp.

$82.39

9.135 (12.47%)

NLS

Nautilus

$7.00

-4.76 (-40.48%)

CASA

Casa Systems

$11.23

-3.17 (-22.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 18

    Jan

  • 18

    Jan

  • 24

    Jan

  • 24

    Jan

  • 29

    Jan

  • 30

    Jan

  • 30

    Jan

  • 25

    Feb

  • 25

    Feb

  • 03

    Mar

SNE

Sony

$50.08

0.58 (1.17%)

16:12
01/18/19
01/18
16:12
01/18/19
16:12
Periodicals
Sony Music ends working relationship with R. Kelly, Variety reports »

Sony Music has opted to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLD

Prologis

$64.58

0.53 (0.83%)

16:12
01/18/19
01/18
16:12
01/18/19
16:12
Hot Stocks
Prologis, Ivanhoe Cambridge form $880M joint venture in Brazil »

Prologis and Ivanhoe…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

CYDY

CytoDyn

$0.00

(0.00%)

16:10
01/18/19
01/18
16:10
01/18/19
16:10
Conference/Events
CytoDyn participates in lunch meeting with Philadelphia Securities »

Luncheon Meeting with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WHF

WhiteHorse Finance

$13.58

-0.105 (-0.77%)

16:09
01/18/19
01/18
16:09
01/18/19
16:09
Hot Stocks
WhiteHorse Finance, STRS Ohio form JV to invest in debt facilities »

WhiteHorse Finance, Inc.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CB

Chubb

$133.43

0.6 (0.45%)

16:07
01/18/19
01/18
16:07
01/18/19
16:07
Hot Stocks
Chubb sees Q4 net catastrophe loss approximately $585M pre-tax, $505M after tax »

Chubb announced net…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

ESEA

Euroseas

$0.80

-0.0332 (-3.98%)

16:07
01/18/19
01/18
16:07
01/18/19
16:07
Hot Stocks
Euroseas receives Nasdaq notice of non-compliance »

Euroseas Ltd. announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRK

Merck

$75.68

0.08 (0.11%)

, SSNLF

Samsung

$0.00

(0.00%)

16:04
01/18/19
01/18
16:04
01/18/19
16:04
Hot Stocks
FDA approves Samsung Bioepis-Merck biosimilar to Roche's Herceptrin »

The FDA announced that it…

MRK

Merck

$75.68

0.08 (0.11%)

SSNLF

Samsung

$0.00

(0.00%)

RHHBY

Roche

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 28

    Jan

  • 01

    Feb

  • 16

    Feb

  • 18

    Mar

  • 11

    Apr

  • 18

    May

NKE

Nike

$80.35

1.23 (1.55%)

15:40
01/18/19
01/18
15:40
01/18/19
15:40
Options
Nike calls lead puts more than 4:1 as shares extend gains »

Nike calls lead puts more…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANIX

Anixa Biosciences

$4.20

-0.05 (-1.18%)

15:37
01/18/19
01/18
15:37
01/18/19
15:37
Conference/Events
Anixa Biosciences to hold a conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.